Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non–small cell lung cancer

Abstract

OBJECTIVE The purpose of this study was to assess the impact of temporal muscle thickness (TMT), a surrogate marker for sarcopenia, in radiosurgically treated patients with brain metastases (BMs) from non–small cell lung cancer (NSCLC). METHODS For 566 patients with BMs from NSCLC in the period between June 2012 and December 2019, TMT values were retrospectively measured on the planning brain magnetic resonance imaging (MRI) studies that had been obtained before their first Gamma Knife radiosurgery treatment (GKRS1). Predefined sex-specific TMT cutoff values were used to stratify the study cohort into patients at risk for sarcopenia and patients with normal muscle status. Cox regression models adjusted for other prognostic parameters were used to evaluate sarcopenia as an independent prognostic factor. RESULTS In sarcopenia patients with a TMT below the sex-specific cutoff values, the risk of death was significantly increased (HR 1.908, 95% CI 1.550–2.349, p < 0.001). In addition, sarcopenia was revealed as an independent prognostic factor even after adjusting for age groups, sex, number of BMs, presence of extracranial metastases, NSCLC subtypes, Karnofsky Performance Status groups, recursive partitioning analysis classes, and concomitant immunotherapy or targeted therapy (HR 1.680, 95% CI 1.347–2.095, p < 0.001). However, patients at risk for sarcopenia showed no significant differences in the estimated mean time until local BM progression after GKRS1, compared to patients with normal muscle status (p = 0.639). CONCLUSIONS TMT obtained from planning MRI studies is an independent prognostic marker in radiosurgically treated patients with BMs from NSCLC and may aid patient stratification in future clinical trials.

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

“…Current systematic review suggests that sarcopenia negatively affects prognostic outcomes of cancer patients in terms of survival, physical activity, length of hospital stay and other complications [16][17][18][19][20][21][22]. However, we found that current studies were limited to specific primary tumors or site-specific metastatic cancers [23][24][25]. While sarcopenia as a systemic disease, we hypothesize that it is closely associated with the prognosis of multiple metastatic cancers.…”

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

“…Current systematic review suggests that sarcopenia negatively affects prognostic outcomes of cancer patients in terms of survival, physical activity, length of hospital stay and other complications (16)(17)(18)(19)(20)(21)(22). However, we found that current studies were limited to speci c primary tumors or site-speci c metastatic cancers (23)(24)(25). While sarcopenia as a systemic disease, we hypothesize that it is closely associated with the prognosis of multiple metastatic cancers.…”

The prognostic utility of temporalis muscle thickness measured on magnetic resonance scans in patients with intra-axial malignant brain tumours: A systematic review and meta-analysis

“…Most of the studies were conducted in Austria (6 studies). 4 , 8 , 24 , 25 , 26 , 27 There were two studies from Turkey, 28 , 29 two from USA, 30 , 31 two from Germany, 32 , 33 two from Italy, 34 , 35 one from South Korea, 36 one from the Netherlands 37 and one from China. 38 Our review includes 17 retrospective cohort studies.…”